首页 > 最新文献

Profiles of drug substances, excipients, and related methodology最新文献

英文 中文
Ponatinib: A comprehensive drug profile. Ponatinib:全面的药物简介。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2024-01-25 DOI: 10.1016/bs.podrm.2023.11.005
Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ali S Abdelhameed, Adnan A Kadi, Sawsan Bushra Hassan, Dalia W Zeidan, Ahmed H Bakheit

Ponatinib is a prescription medication used to treat a rare form of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) that is resistant to other treatments. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking abnormal proteins that promote the growth of cancer cells. In this chapter, the synthesis methods and physicochemical properties of ponatinib were reviewed, besides the characterization of the ponatinib structure using different techniques such as elemental analysis, IR, UV, (1H and 13C) NMR, MS, and XRD. Furthermore, the compendial method for analysis of ponatinib was not found, while the literature review of a non-compendial method for analysis of ponatinib, such as spectroscopic, chromatographic, and immunoassay methods, was covered. Moreover, pharmacology and biochemistry were surveyed in the pharmacokinetic and pharmacodynamic studies.

泊纳替尼是一种处方药,用于治疗一种罕见的血癌,即费城染色体阳性急性淋巴细胞白血病(Ph+ ALL)和对其他疗法耐药的慢性髓性白血病(CML)。它属于一类名为酪氨酸激酶抑制剂的药物,通过阻断促进癌细胞生长的异常蛋白质而发挥作用。在本章中,除了使用元素分析、红外光谱、紫外光谱、(1H 和 13C)核磁共振、质谱和 X 射线衍射等不同技术表征泊纳替尼的结构外,还回顾了泊纳替尼的合成方法和理化性质。此外,还未找到分析泊纳替尼的药典方法,但对分析泊纳替尼的非药典方法(如光谱法、色谱法和免疫测定法)进行了文献综述。此外,还对药代动力学和药效学研究中的药理学和生物化学进行了调查。
{"title":"Ponatinib: A comprehensive drug profile.","authors":"Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ali S Abdelhameed, Adnan A Kadi, Sawsan Bushra Hassan, Dalia W Zeidan, Ahmed H Bakheit","doi":"10.1016/bs.podrm.2023.11.005","DOIUrl":"10.1016/bs.podrm.2023.11.005","url":null,"abstract":"<p><p>Ponatinib is a prescription medication used to treat a rare form of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML) that is resistant to other treatments. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by blocking abnormal proteins that promote the growth of cancer cells. In this chapter, the synthesis methods and physicochemical properties of ponatinib were reviewed, besides the characterization of the ponatinib structure using different techniques such as elemental analysis, IR, UV, (<sup>1</sup>H and <sup>13</sup>C) NMR, MS, and XRD. Furthermore, the compendial method for analysis of ponatinib was not found, while the literature review of a non-compendial method for analysis of ponatinib, such as spectroscopic, chromatographic, and immunoassay methods, was covered. Moreover, pharmacology and biochemistry were surveyed in the pharmacokinetic and pharmacodynamic studies.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deferasirox: A comprehensive drug profile. 地拉罗司:全面的药物简介。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2024-01-22 DOI: 10.1016/bs.podrm.2023.11.001
Mohamed Fawzi Kabil, Maha Nasr

Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.

地拉罗司是诺华公司开发的一种铁螯合剂,用于治疗伴有慢性铁负荷过重的疾病,如β-地中海贫血或镰状细胞疾病。由于它具有高亲和性、特异性和治疗窗口宽等优点,被认为是一线治疗药物。本章介绍了地拉罗司的理化特性、作用模式、药代动力学、治疗应用和合成方法。此外,还包括对其官能团的傅立叶变换红外光谱(FTIR)和核磁共振光谱(NMR)分析。此外,还对选定的分析方法进行了总结,以帮助分析人员对地拉罗司进行常规分析。
{"title":"Deferasirox: A comprehensive drug profile.","authors":"Mohamed Fawzi Kabil, Maha Nasr","doi":"10.1016/bs.podrm.2023.11.001","DOIUrl":"10.1016/bs.podrm.2023.11.001","url":null,"abstract":"<p><p>Deferasirox is an iron-chelating drug developed by Novartis company for treatment of diseases accompanied by chronic iron overload; such as β-thalassemia or sickle cell diseases. Owing to its advantages such as high affinity, specificity and wide therapeutic window, it is considered as first line treatment. The current chapter describes the physicochemical characteristics, mode of action, pharmacokinetics, therapeutic applications and synthetic methods for deferasirox. Moreover, it includes Fourier transform infrared spectrometry (FTIR) and nuclear magnetic resonance spectroscopy (NMR) analysis for its functional groups. In addition, the selected analytical methods are summarized to aid the analysts in their routine analysis of deferasirox.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regorafenib: A comprehensive drug profile. 瑞戈非尼:全面的药物简介。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI: 10.1016/bs.podrm.2023.11.004
Ahmed A Abdelgalil, Hamad M Alkahtani

Regorafenib is a small molecule tyrosine kinase inhibitor administered orally drug, act by inhibiting the activity of the VEGF receptors. It is used for the treatment of patients with metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. This comprehensive profile on regorafenib includes an original data as well as data collected from the literature on Profiles of Methods of Drug Synthesis, different Physical Drug Profiles, Drug Analytical methods and Pharmacological profile (ADME). This chapter is divided into five main sections: General Description of the drug, Physical Characteristics, Methods of Preparation, Methods of Analysis, Pharmacology and List of References. These main sections are further divided to many sub-titles to cover most aspect of the drug in the light of the available literature. Among these sub-titles are the formulae, Elemental Analysis, physical characteristics which include constant of ionization, solubility, X-ray powder diffraction pattern, TGA, thermal conduct and spectroscopic and stability. Additionally, analytical techniques including Electrochemical, Spectrophotometric and chromatographic methods, ADME profiles and pharmacological effects were also discussed. Furthermore, methods and schemes are outlined for the preparation of the drug substance.

瑞戈非尼是一种口服小分子酪氨酸激酶抑制剂,通过抑制血管内皮生长因子受体的活性发挥作用。它用于治疗转移性结直肠癌(CRC)、晚期胃肠道间质瘤和肝细胞癌患者。这篇关于瑞戈非尼的综合资料包括原始数据以及从药物合成方法简介、不同药物物理简介、药物分析方法和药理简介(ADME)等文献中收集的数据。本章分为五个主要部分:药物概述、物理特征、制备方法、分析方法、药理学和参考文献列表。根据现有文献,这些主要部分又分为许多小标题,以涵盖药物的大多数方面。这些小标题包括配方、元素分析、物理特性(包括电离常数、溶解度、X 射线粉末衍射图样、TGA、热导率、光谱和稳定性)。此外,还讨论了包括电化学、分光光度法和色谱法在内的分析技术、ADME 图谱和药理作用。此外,还概述了药物的制备方法和方案。
{"title":"Regorafenib: A comprehensive drug profile.","authors":"Ahmed A Abdelgalil, Hamad M Alkahtani","doi":"10.1016/bs.podrm.2023.11.004","DOIUrl":"10.1016/bs.podrm.2023.11.004","url":null,"abstract":"<p><p>Regorafenib is a small molecule tyrosine kinase inhibitor administered orally drug, act by inhibiting the activity of the VEGF receptors. It is used for the treatment of patients with metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. This comprehensive profile on regorafenib includes an original data as well as data collected from the literature on Profiles of Methods of Drug Synthesis, different Physical Drug Profiles, Drug Analytical methods and Pharmacological profile (ADME). This chapter is divided into five main sections: General Description of the drug, Physical Characteristics, Methods of Preparation, Methods of Analysis, Pharmacology and List of References. These main sections are further divided to many sub-titles to cover most aspect of the drug in the light of the available literature. Among these sub-titles are the formulae, Elemental Analysis, physical characteristics which include constant of ionization, solubility, X-ray powder diffraction pattern, TGA, thermal conduct and spectroscopic and stability. Additionally, analytical techniques including Electrochemical, Spectrophotometric and chromatographic methods, ADME profiles and pharmacological effects were also discussed. Furthermore, methods and schemes are outlined for the preparation of the drug substance.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avanafil: A comprehensive drug profile. 阿伐那非:药物综合概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2023-12-13 DOI: 10.1016/bs.podrm.2023.11.006
Abdulrahman A Al-Majed, Amer AlKhairallah, Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ayman Alkhider, Sawsan Bushra Hassan, Ahmed H Bakheit

Avanafil is an oral medication used to treat erectile dysfunction (ED). As a phosphodiesterase type 5 (PDE5) inhibitor, it functions by inhibiting the PDE5 enzyme, which ultimately results in increased levels of cyclic guanosine monophosphate (cGMP) and improved blood flow to the penis. Approved by the FDA in 2012, avanafil is recognised for its rapid onset of action, short half-life, and favourable side-effects profile. While it has been explored for other potential therapeutic applications, its current approved use is limited to ED and should be used as prescribed by a medical professional. This chapter provides a comprehensive review of avanafil, encompassing its nomenclature, physicochemical properties, methods of preparation, and identification. Various techniques for analysing avanafil, such as electrochemical analysis, spectrophotometric, spectrofluorimetric, and chromatographic techniques, are discussed. The pharmacology of avanafil, including its pharmacokinetics and pharmacodynamics, is also examined.

阿伐那非是一种用于治疗勃起功能障碍(ED)的口服药物。作为一种5型磷酸二酯酶(PDE5)抑制剂,它通过抑制PDE5酶发挥作用,最终导致环磷酸鸟苷(cGMP)水平升高,改善阴茎血流量。阿伐那非于2012年获得美国食品和药物管理局(FDA)批准,因其起效快、半衰期短、副作用小而备受认可。虽然阿伐那非还被用于其他潜在的治疗用途,但其目前获批的用途仅限于ED,应遵医嘱使用。本章全面介绍了阿伐那非,包括其命名、理化性质、制备方法和鉴定。本章讨论了分析阿伐那非的各种技术,如电化学分析、分光光度法、分光荧光法和色谱法。还研究了阿伐那非的药理学,包括其药代动力学和药效学。
{"title":"Avanafil: A comprehensive drug profile.","authors":"Abdulrahman A Al-Majed, Amer AlKhairallah, Mohamed W Attwa, Hamad M Alkahtani, Adel S El-Azab, Alaa A-M Abdel-Aziz, Ayman Alkhider, Sawsan Bushra Hassan, Ahmed H Bakheit","doi":"10.1016/bs.podrm.2023.11.006","DOIUrl":"10.1016/bs.podrm.2023.11.006","url":null,"abstract":"<p><p>Avanafil is an oral medication used to treat erectile dysfunction (ED). As a phosphodiesterase type 5 (PDE5) inhibitor, it functions by inhibiting the PDE5 enzyme, which ultimately results in increased levels of cyclic guanosine monophosphate (cGMP) and improved blood flow to the penis. Approved by the FDA in 2012, avanafil is recognised for its rapid onset of action, short half-life, and favourable side-effects profile. While it has been explored for other potential therapeutic applications, its current approved use is limited to ED and should be used as prescribed by a medical professional. This chapter provides a comprehensive review of avanafil, encompassing its nomenclature, physicochemical properties, methods of preparation, and identification. Various techniques for analysing avanafil, such as electrochemical analysis, spectrophotometric, spectrofluorimetric, and chromatographic techniques, are discussed. The pharmacology of avanafil, including its pharmacokinetics and pharmacodynamics, is also examined.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duvelisib: A comprehensive profile. 杜维力:综合概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2023-12-07 DOI: 10.1016/bs.podrm.2023.11.002
Haya I Aljohar, Ebtehal Al-Abdullah, Nourah Z Alzoman, Hany W Darwish, Ibrahim A Darwish

Duvelisib (DUV) is chemically named as (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one. It is a novel drug with a small molecular weight and characterized by dual phosphoinositide-3-kinase (PI3K)- and PI3K-inhibitory activity. The Food and Drug Administration (FDA) recently approved DUV for the management of small lymphocytic lymphoma (SLL) and relapsed or refractory chronic lymphocytic leukemia (CLL) in adult patients. DUV is marketed under the brand name of Copiktra® (Verastem, Inc., Needham, MA, USA). This chapter provides a critical extensive review of the literature, the description of DUV in terms of its names, formulae, elemental composition, appearance, and use in the treatment of CLL, SLL, and follicular lymphoma. The chapter also describes the methods for preparation of DUV, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.

杜维力(DUV)的化学名称为(S)-3-(1-((9H-嘌呤-6-基)氨基)乙基)-8-氯-2-苯基异喹啉-1(2H)-酮。它是一种分子量较小的新型药物,具有磷酸肌酸-3-激酶(PI3K)和 PI3K 双重抑制活性。美国食品和药物管理局(FDA)最近批准 DUV 用于治疗成人小淋巴细胞淋巴瘤(SLL)和复发或难治性慢性淋巴细胞白血病(CLL)。DUV 以 Copiktra® (Verastem, Inc., Needham, MA, USA)的品牌在市场上销售。本章对文献进行了批判性的广泛回顾,从名称、配方、元素组成、外观以及治疗 CLL、SLL 和滤泡性淋巴瘤的用途等方面对 DUV 进行了描述。本章还介绍了 DUV 的制备方法、物理化学性质、分析测定方法、药理性质和剂量信息。
{"title":"Duvelisib: A comprehensive profile.","authors":"Haya I Aljohar, Ebtehal Al-Abdullah, Nourah Z Alzoman, Hany W Darwish, Ibrahim A Darwish","doi":"10.1016/bs.podrm.2023.11.002","DOIUrl":"10.1016/bs.podrm.2023.11.002","url":null,"abstract":"<p><p>Duvelisib (DUV) is chemically named as (S)-3-(1-((9H-Purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one. It is a novel drug with a small molecular weight and characterized by dual phosphoinositide-3-kinase (PI3K)- and PI3K-inhibitory activity. The Food and Drug Administration (FDA) recently approved DUV for the management of small lymphocytic lymphoma (SLL) and relapsed or refractory chronic lymphocytic leukemia (CLL) in adult patients. DUV is marketed under the brand name of Copiktra® (Verastem, Inc., Needham, MA, USA). This chapter provides a critical extensive review of the literature, the description of DUV in terms of its names, formulae, elemental composition, appearance, and use in the treatment of CLL, SLL, and follicular lymphoma. The chapter also describes the methods for preparation of DUV, its physical-chemical properties, analytical methods for its determination, pharmacological properties, and dosing information.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective. 草药的监管和标准化:现状、局限性、挑战和未来展望。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-01-01 Epub Date: 2023-12-12 DOI: 10.1016/bs.podrm.2023.11.003
Gunawan Indrayanto

Herbal drugs (HD) or traditional drugs have been used worldwide for centuries, especially in the developing countries. Global market of HD reaches billion of USD annually and increases every year. For ensuring the safety and efficacy of HD, the Drug Agency/Authority issues regulations for the registration & application of new HD, their manufacturing processes, controlling and monitoring in the market. The efficacy and safety of HD depend on their whole chemical contents. Quality assessment of HD should be performed using standardization methods according to the current Pharmacopoeias or Materia Medica. Unfortunately, the official methods of the compendia cannot be applied for evaluation of mixed herbs and their preparations.; HD's producers should develop, validate, and standardize the method for the quality assessment of their own specific products. Therefore, assuring the safety and efficacy of HD remains a challenging task due to the complex nature of HD, that typically consist of many constituents of herbs/extracts whose quality may vary among different sources of materials. This present review will describe, compare, and discuss the regulations and standardization methods of HD from US, EU countries, Japan, Taiwan, Hong Kong and Indonesia. The official standardization methods of HD, their current criteria, limitations, challenge and future prospective will be described and discussed. Official methods for quality assessment of HD should be state of the art, fast, low-cost, accurate and precise, and could be used for evaluation of all kinds of HD.

草药(HD)或传统药物已在全球使用了几个世纪,尤其是在发展中国家。全球草药市场每年达到数十亿美元,并且每年都在增长。为确保草药的安全性和有效性,药品管理局/主管部门对新草药的注册和应用、生产工艺、市场控制和监测发布了相关规定。人类免疫缺损病毒的疗效和安全性取决于其全部化学成分。应根据现行的《药典》或《本草纲目》,采用标准化方法对人类免疫缺损病毒进行质量评估。遗憾的是,药典中的官方方法不能用于评估混合药材及其制剂。因此,确保人类免疫缺损病毒的安全性和有效性仍然是一项具有挑战性的任务,因为人类免疫缺损病毒的性质复杂,通常由多种草药/提取物成分组成,不同来源的材料质量可能不同。本综述将介绍、比较和讨论美国、欧盟国家、日本、台湾、香港和印度尼西亚的 HD 法规和标准化方法。将对 HD 的官方标准化方法、其现行标准、局限性、挑战和未来前景进行描述和讨论。HD 质量评估的官方方法应是最先进的、快速的、低成本的、准确的和精确的,并可用于各种 HD 的评估。
{"title":"Regulation and standardization of herbal drugs: Current status, limitation, challenge's and future prospective.","authors":"Gunawan Indrayanto","doi":"10.1016/bs.podrm.2023.11.003","DOIUrl":"10.1016/bs.podrm.2023.11.003","url":null,"abstract":"<p><p>Herbal drugs (HD) or traditional drugs have been used worldwide for centuries, especially in the developing countries. Global market of HD reaches billion of USD annually and increases every year. For ensuring the safety and efficacy of HD, the Drug Agency/Authority issues regulations for the registration & application of new HD, their manufacturing processes, controlling and monitoring in the market. The efficacy and safety of HD depend on their whole chemical contents. Quality assessment of HD should be performed using standardization methods according to the current Pharmacopoeias or Materia Medica. Unfortunately, the official methods of the compendia cannot be applied for evaluation of mixed herbs and their preparations.; HD's producers should develop, validate, and standardize the method for the quality assessment of their own specific products. Therefore, assuring the safety and efficacy of HD remains a challenging task due to the complex nature of HD, that typically consist of many constituents of herbs/extracts whose quality may vary among different sources of materials. This present review will describe, compare, and discuss the regulations and standardization methods of HD from US, EU countries, Japan, Taiwan, Hong Kong and Indonesia. The official standardization methods of HD, their current criteria, limitations, challenge and future prospective will be described and discussed. Official methods for quality assessment of HD should be state of the art, fast, low-cost, accurate and precise, and could be used for evaluation of all kinds of HD.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remdesivir
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-02-01 DOI: 10.1007/s40278-023-34554-z
Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn
{"title":"Remdesivir","authors":"Ahmed H H Bakheit, H. Darwish, I. Darwish, Ahmed I. Al-Ghusn","doi":"10.1007/s40278-023-34554-z","DOIUrl":"https://doi.org/10.1007/s40278-023-34554-z","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79027077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preface. 前言。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/S1871-5125(23)00009-2
Abdulrahman A Al-Majed
{"title":"Preface.","authors":"Abdulrahman A Al-Majed","doi":"10.1016/S1871-5125(23)00009-2","DOIUrl":"https://doi.org/10.1016/S1871-5125(23)00009-2","url":null,"abstract":"","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9361385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crizotinib: A comprehensive profile. 克唑替尼:全面概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.002
Ahmed A Abdelgalil, Hamad M Alkahtani

Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.

克唑替尼于2011年获批,是首个获批靶向间变性淋巴瘤激酶(ALK)的抑制剂,用于治疗间变性淋巴瘤激酶(ALK)阳性的转移性非小细胞肺癌(NSCLC)患者。本章对克唑替尼的命名、理化性质、制备方法、鉴定技术、各种定性和定量分析技术以及克唑替尼的药理学等方面进行了全面的综述。此外,本章还回顾了几种使用色谱技术分离克唑替尼的方法。
{"title":"Crizotinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.002","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.002","url":null,"abstract":"<p><p>Crizotinib, approved in 2011, was the first approved inhibitor targeting anaplastic lymphoma kinase (ALK) It used for treatment of the patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive. This chapter provides a complete review of crizotinib including nomenclature, physiochemical properties, methods of preparation, identification techniques and various qualitative and quantitative analytical techniques as well as pharmacology of crizotinib. In addition, the chapter also includes review of several methods for separation of crizotinib using chromatographic techniques.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lapatinib: A comprehensive profile. 拉帕替尼:全面的概况。
Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-01-01 DOI: 10.1016/bs.podrm.2022.11.005
Ahmed A Abdelgalil, Hamad M Alkahtani

Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods are indicated. Other studies on this drug substance include drug stability, pharmaceutical applications, mechanism of action, pharmacodynamics, and a dosing information are also reviewed.

拉帕替尼是一种抗癌药物,用于治疗晚期转移性乳腺癌患者,与化疗药物卡培他滨或来曲唑联合用于治疗绝经后激素受体阳性转移性乳腺癌妇女。拉帕替尼的综合简介提供了更详细的信息,包括描述、配方、元素分析、用途和应用。此外,还概述了该原料药的制备方法和方案。研究了药物的物理性质,包括电离常数、溶解度、x射线粉末衍射图、差示扫描量热、热传导和光谱研究。原料药和/或制剂中用于分析原料药的方法包括分光光度法、电化学法和色谱法。对该原料药的其他研究包括药物稳定性、药物应用、作用机制、药效学和给药信息进行了综述。
{"title":"Lapatinib: A comprehensive profile.","authors":"Ahmed A Abdelgalil,&nbsp;Hamad M Alkahtani","doi":"10.1016/bs.podrm.2022.11.005","DOIUrl":"https://doi.org/10.1016/bs.podrm.2022.11.005","url":null,"abstract":"<p><p>Lapatinib is an anticancer used for treatment of the patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine or with letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer. This comprehensive profile of Lapatinib gives more detailed information about the description, formulae, Elemental Analysis, Uses and application. Furthermore, methods and schemes are outlined for the preparation of the drug substance. The physical properties of the medication include constant of ionization, solubility, X-ray powder diffraction pattern, differential scanning calorimetry, thermal conduct and spectroscopic studies are investigated. The methods employed in bulk medicines and/or in pharmaceutical formulations to analyze the drug substance include spectrophotometric, electrochemical and the chromatographic methods are indicated. Other studies on this drug substance include drug stability, pharmaceutical applications, mechanism of action, pharmacodynamics, and a dosing information are also reviewed.</p>","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9315709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Profiles of drug substances, excipients, and related methodology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1